Saturday, August 2, 2025 8/2/2025

ENHANCING NATIVE AMERICAN PARTICIPATION IN RT TRIALS

Award Number: U56CA099010
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/27/2002
PERIOD OF PERFORMANCE END DATE: 08/31/2009

Group Awards By:

View Award Description

ENHANCING NATIVE AMERICAN PARTICIPATION IN RT TRIALS - DESCRIPTION (provided by applicant): The Cancer Care Institute (CCI) in Rapid City, South Dakota, serves approximately 100,000 Native Americans from three reservations. Some patients live up to four hours from the cancer center. Identifying barriers which prevent Native Americans from presenting with earlier stages of cancer, or in some circumstances not at all, will be investigated. A culturally responsive questionnaire will be administered to randomly selected Native Americans on the reservation who do not have cancer. A second questionnaire will be given to cancer patients, and address similar issues, but concentrate on additional questions of oncologic relevance. It is hypothesized that a major barrier is geographic dislocation from cultural/community roots close to home. Traditional radiotherapy involves a 6 to 8 week course and daily treatments. This treatment approach may represent a major barrier. With the use of advanced technologies such as intensity modulated radiotherapy and brachytherapy, the treatment course can be shortened to 1 to 4 weeks. Therefore, to address this barrier, clinical trials have been developed which shorten treatment duration. A series of phase II studies are proposed for malignancies commonly seen among the Native Americans: metastatic disease, non-small cell lung (NSCLC), breast, prostate and head and neck (H and N) cancer. For patients with stage I and II breast cancer, high-dose-rate (HDR) brachytherapy will be substituted for a conventional course of external beam radiation. Patients with advanced prostate cancer will be treated with a 2 week course of conformal external beam radiation followed by an HDR implant in combination with androgen ablation. Pilot tomotherapy trials are proposed for patients with metastatic disease, locally advanced H&N, and NSCLC. The final pilot trial will investigate the use of HDR brachytherapy alone for early stage prostate cancer. A genetic milieu may exist which renders Native Americans more sensitive to radiation. Therefore, a laboratory study will be conducted to investigate whether Native Americans have a higher mutation rate of the AT (ataxia-telangiectasia) gene determined through HPLC of the peripheral blood lymphocytes. Through patient education, screening, assessing potential barriers to health care, and innovative treatment strategies, it is hoped that Native Americans will eventually present earlier in their disease process.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2009 ( Subtotal = $0 )
2009	2008	RAPID CITY REGIONAL HOSPITAL INC	POST OFFICE BOX 6000	RAPID CITY	SD	57709	PENNINGTON	USA	Cancer Control	003	6	2/24/2009	SUPPLEMENT FOR EXPANSION	$0
2009	2007	RAPID CITY REGIONAL HOSPITAL INC	POST OFFICE BOX 6000	RAPID CITY	SD	57709	PENNINGTON	USA	Cancer Control	001	6	2/24/2009	SUPPLEMENT FOR EXPANSION	$0
2009	2007	RAPID CITY REGIONAL HOSPITAL INC	POST OFFICE BOX 6000	RAPID CITY	SD	57709	PENNINGTON	USA	Cancer Cause and Prevention Research	000	6	2/24/2009	NON-COMPETING CONTINUATION	$0
2009	2007	RAPID CITY REGIONAL HOSPITAL INC	POST OFFICE BOX 6000	RAPID CITY	SD	57709	PENNINGTON	USA	Cancer Control	002	6	2/24/2009	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $0

Issue Date FY: 2008 ( Subtotal = $100,000 )
2008	2008	RAPID CITY REGIONAL HOSPITAL INC	POST OFFICE BOX 6000	RAPID CITY	SD	57709	PENNINGTON	USA	Cancer Control	003	6	8/28/2008	SUPPLEMENT FOR EXPANSION	$100,000
														Subtotal = $100,000

Issue Date FY: 2007 ( Subtotal = $1,106,269 )
2007	2007	RAPID CITY REGIONAL HOSPITAL INC	POST OFFICE BOX 6000	RAPID CITY	SD	57709	PENNINGTON	USA	Cancer Cause and Prevention Research	000	6	8/21/2007	NON-COMPETING CONTINUATION	$543,034
2007	2007	RAPID CITY REGIONAL HOSPITAL INC	POST OFFICE BOX 6000	RAPID CITY	SD	57709	PENNINGTON	USA	Cancer Control	002	6	9/10/2007	SUPPLEMENT FOR EXPANSION	$244,353
2007	2007	RAPID CITY REGIONAL HOSPITAL INC	POST OFFICE BOX 6000	RAPID CITY	SD	57709	PENNINGTON	USA	Cancer Control	001	6	8/23/2007	SUPPLEMENT FOR EXPANSION	$318,882
														Subtotal = $1,106,269

Issue Date FY: 2006 ( Subtotal = $1,182,097 )
2006	2006	RAPID CITY REGIONAL HOSPITAL INC	POST OFFICE BOX 6000	RAPID CITY	SD	57709	PENNINGTON	USA	Cancer Cause and Prevention Research	000	5	9/12/2006	NON-COMPETING CONTINUATION	$1,182,097
														Subtotal = $1,182,097

Issue Date FY: 2004 ( Subtotal = $307,973 )
2004	2004	RAPID CITY REGIONAL HOSPITAL INC	POST OFFICE BOX 6000	RAPID CITY	SD	57709	PENNINGTON	USA	Cancer Cause and Prevention Research	000	3	9/9/2004	NON-COMPETING CONTINUATION	$307,973
														Subtotal = $307,973

Issue Date FY: 2003 ( Subtotal = $996,038 )
2003	2003	RAPID CITY REGIONAL HOSPITAL INC	POST OFFICE BOX 6000	RAPID CITY	SD	57709	PENNINGTON	USA	Cancer Cause and Prevention Research	000	2	8/25/2003	NON-COMPETING CONTINUATION	$896,038
2003	2003	RAPID CITY REGIONAL HOSPITAL INC	POST OFFICE BOX 6000	RAPID CITY	SD	57709	PENNINGTON	USA	Cancer Treatment Research	001	2	8/26/2003	SUPPLEMENT FOR EXPANSION	$100,000
														Subtotal = $996,038

Issue Date FY: 2002 ( Subtotal = $1,404,486 )
2002	2002	RAPID CITY REGIONAL HOSPITAL INC	POST OFFICE BOX 6000	RAPID CITY	SD	57709	PENNINGTON	USA	Cancer Cause and Prevention Research	000	1	9/27/2002	NEW	$1,404,486
														Subtotal = $1,404,486

Grand Total All Awards = $5,096,863

Top

All Categories

About

Search

Reports

Data Submission

Award Information

ENHANCING NATIVE AMERICAN PARTICIPATION IN RT TRIALS

Award Number: U56CA099010

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/27/2002

PERIOD OF PERFORMANCE END DATE: 08/31/2009

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer